Click here if you are having trouble viewing this message. 

   

 

IAVI E-Newsletter: World AIDS Vaccine Day 
IAVI's News
Research Updates
Partner Updates
Funding Updates
IAVI In The News

On World AIDS Vaccine Day, May 18, IAVI remains as committed to the quest for an AIDS vaccine as it was in 1998, when this day of observance was established to commemorate former US President Bill Clinton’s challenge to researchers to develop a vaccine against HIV. We are as committed as we were when, 13 years ago, world leaders established the Millennium Development Goals and included in their ambitious list a call to address the suffering caused by AIDS, halt the growth of the HIV pandemic by 2015 and begin reversing the tide of new infections. In the face of serious scientific and economic challenges—and acknowledging the remarkable progress that has already been made in the prevention and treatment of HIV and AIDS—we remain committed to the belief that the world needs an AIDS vaccine. 

IAVI acknowledges the valuable role volunteers, communities, governments, policy makers, donors, industry, health professionals and academic researchers around the world play in this collective effort. We invite the international community to join us in celebrating their contributions and urge continued support for HIV vaccine development as part of a comprehensive response to the HIV pandemic.
On HIV Vaccine Awareness Day/ World AIDS vaccine Day, IAVI CEO Margie McGlynn Reflects on Research Setbacks and Progress in a USAID Impact Blog Post
Few things really worth having are easily obtained. This old saw, though well worn, applies perfectly to vaccines. And it bears repeating as we approach HIV Vaccine Awareness Day—especially in light of the recent termination of HVTN 505, a clinical trial testing whether a candidate vaccine regimen could prevent HIV infection or slow progression to AIDS. The trial was halted when it became clear the regimen would fall short on both goals.

This is disappointing news; yet history has taught us that such setbacks are par for the course in vaccine development. This is the nature of the effort: vaccine researchers learn through informed trial and error what works, and what does not, and use that knowledge to hone their strategies. Most importantly, we must emphasize that the termination of HVTN 505 occurs against a backdrop of remarkable progress in HIV vaccine development. Though we will probably face some setbacks, researchers are making brisk progress toward that goal. All the evidence today suggests that, if we persevere, it is just a matter of time before HIV vaccines become available. That should serve as a source of inspiration to all of us on this HIV Vaccine Awareness Day.
IAVI Congratulates Marijke Wijnroks on Global Fund Appointment
IAVI congratulates board member Marijke Wijnroks on her appointment as Chief of Staff at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Dr. Wijnroks has a long track record of leadership in the global fight against HIV/AIDS, and a strong commitment to prioritizing sexual reproductive health and rights and other global health issues in national and global development and health agendas. As the Netherlands’ Ambassador for Sexual and Reproductive Health and Rights and HIV/AIDS, she has been an invaluable source of advice and support for IAVI as we pursue our mission to develop a safe and effective AIDS vaccine.
IAVI and Partners Initiate Phase I Trial of a Novel AIDS Vaccine Regimen
IAVI and Japanese biotech DNAVEC announced in April the start of a multi-center Phase I clinical trial to evaluate the safety and tolerability of a novel, preventive HIV vaccine candidate, SeV-G. Researchers also seek to obtain a preliminary assessment of the immune responses elicited by a prime-boost regimen of SeV-G and a vaccine candidate based on adenovirus serotype 35. This clinical trial is the first ever to test SeV-G. Vaccinations in the trial, which is sponsored by IAVI, commenced April 1 at Project San Francisco in Kigali, Rwanda. The trial will also be conducted at the St. Stephen’s Center in London, United Kingdom and, pending final approval, at an additional research center in East Africa.
NIH Announces Discontinuation of Immunizations in AIDS Vaccine Clinical Trial HVTN505
The US National Institute of Allergy and Infectious Diseases announced that a Phase IIb clinical trial, HVTN 505, evaluating a sequential regimen of two HIV vaccine candidates has been halted. The decision was based on the outcome of an interim analysis that indicated the regimen is not likely to prevent HIV infection or suppress the amount of HIV in the blood of vaccine recipients who became infected with HIV. Though disappointed by this outcome, IAVI applauds the sponsors of the trial for completing an important, well conducted and carefully designed study.  An AIDS Vaccine will be an essential tool in the fight against HIV and AIDS.   
Study Published in Nature Follows the Evolution of a Broadly Neutralizing Antibody and Provides Clues for HIV Vaccine Design
A study led by Barton Haynes, director at the Duke Human Vaccines Institute, traced the evolution of HIV in the blood of a single African volunteer from the earliest stages of infection. Published in the journal Nature, the study also charted the evolution of the antibody response to the constantly mutating virus—up to the point where the volunteer produced a broadly neutralizing antibody (bNAb) against HIV, about two years later. By describing this pathway, the study offers guidance for the design of vaccines that elicit bNAbs capable of preventing HIV infection and clues about how to speed the maturation of bNabs in response to vaccination.
Researchers Develop a Promising New Technology to Aid HIV Vaccine Design
A team of researchers from The Scripps Research Institute and IAVI report in the journal Science a novel strategy to aid the design of vaccines that can elicit broadly neutralizing antibodies against HIV. Their approach, which applies pioneering computational and genetic engineering techniques to create an HIV immunogen—the active ingredient of a vaccine—could have significant implications for the design of preventive vaccines against a wide variety of other pathogens as well. 
PDPs Applaud Japan's First Public-Private Partnership to Spearhead Innovation in Global Health
As a Product Development Partnership (PDP) dedicated to the discovery, development and delivery of new global health tools, IAVI applauds the official launch of the Global Health Innovation and Technology Fund (GHIT Fund), announced on 8 April 2013 in Tokyo, Japan. This new public-private partnership of the Japanese government, the Bill & Melinda Gates Foundation and a group of private pharmaceutical companies seek to foster and harness Japanese innovation to address diseases that disproportionately affect low- and middle-income countries. The GHIT Fund complements Japan’s existing investments in critical global health interventions, and demonstrates the nation’s commitment to long-term solutions to develop tools urgently needed to address diseases that impact millions of people, mostly in developing countries. The GHIT Fund will encourage partnerships between world-class Japanese research programs and global efforts by PDPs to advance innovative ideas to discover, develop and deliver medicines, vaccines and other preventive and diagnostic tools for use throughout the world. 
Funding Updates
IAVI gratefully acknowledges a generous pledge of in-kind support from the EMMES Corporation for 2013. As a long-standing partner, EMMES plays an important role in the clinical work and data management that is essential to our mission to ensure the development of an AIDS vaccine.  We appreciate the professional and personal commitment from The EMMES Corporation and its staff and we are proud to have EMMES as a partner.
IAVI is pleased to welcome two GSK PULSE Volunteers to its Human Immunology Laboratory (HIL) at Imperial College in London. The GSK employees will work with IAVI staff over the next six months to assist with quality assurance and assay development assignments.  The GSK PULSE Volunteer Partnership is an integral part of GSK's commitment to serving communities around the world and empowers employees to make a sustainable difference for communities and patients in need.  
IAVI In The News
Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines co-authored by IAVI CSO Wayne Koff & CEO Margie McGlynn, IAVI et al., appearing in Elsevier Vaccine supplement, April 18, 2013

HIV Vaccines – Novel approaches, funding, and clinical studies, summary of World Vaccine Congress session featuring IAVI’s Dr. Rick King, VP Vaccine Design, April 22, 2013



IAVI'S EFFICIENCY 


Eight-five percent of IAVI's revenue is dedicated to program costs. IAVI consistently demonstrates efficient management of resources, earning Charity Navigator three-star rating for good financial management, effectiveness, and transparency.


Copyright © 2012 International AIDS Vaccine Initiative. All rights reserved. International AIDS Vaccine Initiative,
IAVI and the IAVI logo are trademarks of the International AIDS Vaccine Initiative, Inc.

International AIDS Vaccine Initiative
NEW YORK   |   AMSTERDAM   |   JOHANNESBURG   |   LA JOLLA   |   LONDON   |   NAIROBI   |   NEW DELHI 
Click here if you don't wish to receive these messages in the future.